$0.64
▲ +$0.05
(+8.45%)
Vol 4.8M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$185.4M
ROE
7.4%
Margin
1703.1%
D/E
425.44
Beta
2.00
52W
$1–$6
Wall Street Consensus
13 analysts · Apr 20263
Strong Buy
8
Buy
2
Hold
0
Sell
0
Strong Sell
84.6%
Buy Rating
Price Chart
Similar Stocks
CBUS
Cibus Inc
$94.5M
BDTX
Black Diamond Therapeutics Inc
P/E 6.4
$138.4M
KLRS
Kalaris Therapeutics Inc
$141.3M
AGEN
Agenus Inc
$106.8M
EQ
Equillium Inc
$94.4M
IMDX
Insight Molecular Diagnostics Inc
$215.0M
PEPG
PepGen Inc
$447.6M
GNLX
Genelux Corp
$165.9M
SGMO
Sangamo Therapeutics Inc
$141.3M
BMEA
Biomea Fusion Inc
$87.7M
Earnings
Beat rate: 80.0%
Next Report
May 11, 2026
EPS Estimate: $-0.11
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.11 | — | — |
| Dec 2025 | $-0.13 | $-0.13 | +$0.00 |
| Sep 2025 | $-0.16 | $-0.11 | +$0.05 |
| Jun 2025 | $-0.16 | $-0.24 | $-0.08 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | $517K | $301K | $753K |
| Net Income | -$39.2M | -$20.9M | $39.1M | -$37.7M | -$17.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 7.4% | 108.6% | 7.4% | 7.4% | 7.4% | 7.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | 7570.4% | 7570.4% | 7570.4% | 7570.4% | 1703.1% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 425.44 | 48.66 | 425.44 | 425.44 | 425.44 | 425.44 |
| Current Ratio | 2.45 | 3.68 | 2.45 | 2.45 | 2.45 | 1.62 |
Key Ratios
ROA (TTM)
-27.9%
P/S (TTM)
145.96
P/B
21.7
EPS (TTM)
$-0.22
CF/Share
$-0.79
52W High
$5.66
52W Low
$1.04
$1.04
52-Week Range
$5.66
Financial Health
Free Cash Flow
-$24.0M
Net Debt
$10.3M
Cash
$19.5M
Total Debt
$29.8M
As of Sep 30, 2025
How does HUMA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
HUMA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
146.0
▲
1036%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
21.7
▲
783%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
HUMA profitability vs Biotechnology peers
ROE
7.4%
▲
111%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
1703.1%
▲
694%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-27.9%
▲
40%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
HUMA financial health vs Biotechnology peers
D/E ratio
425.4
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.6
▼
64%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
2.0
▲
106%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
HUMA fundamentals radar
HUMA
Peer median
Industry
HUMA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
HUMA vs peers: key metrics
Top Holders
Top 5: 15.65%Blackrock Inc.
6.06%
$7.4M
Vanguard Group Inc
4.49%
$5.5M
Geode Capital Management, L…
1.99%
$2.4M
UBS Group AG
1.59%
$1.9M
State Street Corporation
1.52%
$1.8M
As of Dec 31, 2025
Latest News
The great care home cash grab: how private equity turned vulnerable elderly …
The Guardian · Mar 28
Did Melania Trump's White House Walk With Humanoid Robot Signal Admin's Push …
ZeroHedge · Mar 27
Amazon Is Entering the Humanoid Robot Market. 3 Important Things to Know …
Nasdaq · Mar 26
Amazon acquires 'approachable' humanoid maker Fauna Robotics
CNBC · Mar 24
What sets human consciousness apart from AI? – podcast
The Guardian · Mar 24